Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access |
Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc |
Journal website http://www.gastrores.org |
Original Article
Volume 10, Number 6, December 2017, pages 334-338
ELISA Serology for Antibodies Against Chlamydia trachomatis in Crohn’s Disease
Figure
Tables
Sample group | Families studies | Sporadic cases | |||||
---|---|---|---|---|---|---|---|
Healthy controls for multiplex families (n = 49) | Healthy relatives*, in multiplex families (n = 25) | CD in multiplex families (n = 25) | CD pediatric-onset (n = 80) | UC pediatric-onset (n = 20) | CD adult-onset (n = 148) | UC adult-onset (n = 50) | |
CD: Crohn’s disease; UC: ulcerative colitis. *Healthy first degree relatives of CD patients in multiplex families. | |||||||
IgG positives | 4 (8%) | 2 (8%) | 5 (20%) | 1 (1%) | 2 (10%) | 14 (9%) | 5 (10%) |
IgA positives | 5 (10%) | 2 (8%) | 5 (20%) | 8 (10%) | 1 (5%) | 15 (10%) | 3 (6%) |
Either IgG or IgA positive or both | 7 (14%) | 3 (12%) | 6 (24%) | 9 (11%) | 3 (15%) | 28 (19%) | 7 (14%) |
Male % | 37% | 44% | 40% | 45% | 35% | 43% | 46% |
Age median (min - max) | 39 (16 - 78) | 41 (17 - 78) | 35 (17 - 79) | 24 (16 - 37) | 26 (20 - 35) | 31 (17 - 65) | 40 (18 - 70) |
Author | Year | Country | Ab | Antigen | Test | N | Ctr | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
+ | Total | % | + | Total | % | ||||||
Ab: antibody; Ctr: control; ELISA: enzyme-linked immunosorbent assay. *7.4% were positive to serovars A-K or 207. | |||||||||||
Rodaniche et al [5] | 1943 | US | C. trachomatis LGV | SN | 0 | 4 | 0 | ||||
Swarbrick et al [6] | 1979 | England | IgG | C. trachomatis A-K, 207, LGV 1-3 | Micro FA | 4 | 54 | 7.4* | 10 | 75 | 13 |
Taylor-Robbinson et al [7] | 1979 | England | C. trachomatis B, D-J, LGV 1-3 | Micro FA | 8 | 55 | 14.5 | 5 | 23 | 22 | |
Schuller et al [10] | 1979 | Holland | IgG | C. trachomatis A-K, LGV 1-3 | Micro FA | 38 | 55 | 69 | 1 | 50 | 2 |
Mardh et al [11] | 1980 | Sweden | IgG | C. trachomatis D-K, LGV 1-3 | IIF | 83 | 107 | 78 | 38 | 50 | 76 |
Gump et al [12] | 1981 | US | C. trachomatis LGV 2 | IIF | 35 | 58 | 60 | 33 | 58 | 57 | |
Elliot et al [8] | 1981 | England | C. trachomatis A-K, LGV 1-3 | Micro FA | 0 | 62 | 0 | 3 | 160 | 2 | |
Orda et al [13] | 1990 | Israel | IgG | C. trachomatis | IIP | 14 | 15 | 93 | 4 | 15 | 26 |
Orda et al [13] | 1990 | Israel | IgA | C. trachomatis | IIP | 5 | 15 | 33 | 1 | 15 | 6 |
McGarity et al [9] | 1991 | England | IgG | C. trachomatis L1 | ELISA | 7 | 48 | 15 | 14 | 48 | 29 |
Van Kruiningen et al [4] | 2016 | France | IgG | C. trachomatis LGV 2: 434 | ELISA | 2 | 24 | 8.3 | 1 | 15 | 6.6 |
IgA | C. trachomatis LGV 2: 434 | ELISA | 4 | 24 | 16.6 | 1 | 15 | 6.6 | |||
Gump et al [12] | 1981 | US | IgA | Chlamydia group antigen | CF | 58 | 9.5 | 1 | 58 | 1.7 | |
Swarbrick et al [6] | 1979 | England | IgG | C.psittaci | Micro FA | 0 | 54 | 0 | 0 | 75 | 0 |
Munro et al [14] | 1979 | Wales | IgG | C. psittaci | CF | 30 | 62 | 48 | 18 | 57 | 32 |
Elliot et al [8] | 1981 | England | IgG | C. psittaci | Micro FA | 0 | 62 | 0 | 0 | 160 | 0 |
Van Kruiningen et al [15] | 2000 | France | IgG | C. psittaci | CF | 5 | 13 | 38 | 1 | 13 | 8 |